HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Marketing in Brief: Vilana

This article was originally published in The Rose Sheet

Executive Summary

Vilana: Developing infomercials for Skin-Cap treatment, which "relieves itching, flaking, red and inflamed skin" caused by eczema, seborrhea, dermatitis and dandruff, the Los Angeles-based distributor said. "Skin-Cap causes virtually no side effects and results can be achieved between three days and four weeks depending on the individual's skin condition," the company said. Skin-Cap shampoo and spray have been available in the U.S. since 1995 via direct-marketing channels, and are promoted in The New York Times Magazine, The L.A. Times Magazine and USA Today, Vilana said. Manufactured by Cheminova International Labs (Spain), the shampoo contains 1% pyrithione zinc and .25% menthol, while the spray on treatment is .2% pyrithione zinc. The shampoo and spray are sold together for $38.95 including shipping and handling. Vilana is also planning cream and soap additions to the Skin-Cap line-up...
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS003743

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel